When to Initiate HIV Therapy: A Control Theoretic Approach

IEEE Transactions on Biomedical Engineering

Volumn 50, Issue 11, 2003, Pages 1213-1220

  Jeffrey, Annah M ^a   Xia, Xiaohua ^a   Craig, Ian K ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Chemotherapy; Controllability; HIV; Initiate therapy; Singular value

Indexed keywords

DISEASES; DRUG THERAPY; HEALTH; VIRUSES;

HUMAN IMMUNODEFICIENCY VIRUS (HIV);

BIOMEDICAL ENGINEERING;

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; THEORY; TREATMENT PLANNING; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; COMPUTER SIMULATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG THERAPY, COMPUTER-ASSISTED; HIV; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; POPULATION DYNAMICS; SYSTEMS THEORY; VIRAL LOAD;

EID: 0242363807     PISSN: 00189294     EISSN: None     Source Type: Journal    
DOI: 10.1109/TBME.2003.818465     Document Type: Article

References (35)

1. J. Alvarez-Ramirez, M. Meraz, and J. X. Velasco-Hermandez, "Feedback control of the chemotherapy of HIV," Int. J. Bifurcation Chaos, vol. 10, pp. 2207-2219, 2000.
2. S. L. Becker and R. M. W. Hoetelmas. Exploiting Pharmacokinetics to Optimize Antiretroviral Therapy, Medscape's CME Activity. [Online]. Available: http://www.medscape.com/viewprogram/703index
3. S. Bonhoeffer and M. A. Nowak, "Pre-existence and emergence of drug resistance in HIV-1," Proc. Roy. Soc. London B, vol. 264, pp. 631-637, 1997.
4. M. E. Brandt and G. Chen, "Feedback control of a biodynamical model of HIV-1," IEEE Trans. Biomed. Eng., vol. 48, pp. 754-759, July 2001.
5. S. Butler, D. Kirschner, and S. Lenhart, "Optimal control of chemotherapy affecting the infectivity of HIV," in Advances in Mathematical Populations Dynamics: Molecules, Cells, Man, Singapore: World Scientific, 1997, pp. 104-120.
6. + T cells during primary HIV-1 infection," Proc. Nat. Acad. Sci. USA, vol. 95, pp. 8869-8873, 1998.
7. "MRC/ANRS randomized double-blind controlled trial of immediate and deferred AZT in symptom free HIV infection," Lancet, vol. 343, pp. 871-881, 1994.
8. D. C. Douek, R. D. McFarland, and P. H. Keiser, "Changes in thymic function with the age and during treatment of HIV infection," Nature, vol. 396, pp. 690-695, 1998.
9. J. A. M. F. de Souza, M. A. L. Caetano, and T. Yoneyama, "Optimal control theory applied to the anti-viral treatment of AIDS," presented at the IEEE Conf. Decision and Control, Sydney, Australia, 2000.
10. N. M. Ferguson, C. Fraser, and R. M. Anderson, "Viral dynamics and anti-viral pharmacodynamics: Rethinking in vitro measures of drug potency, " Trends Pharm. Sci., vol. 22, pp. 97-100, 2001.
11. D. Finzi, M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano, "Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy," Science, vol. 278, pp. 1295-1300, 1997.
12. R. M. W. Hoetelmans et al., "The effect of plasma drug concentrations on HIV-1 clearanace rate during quadruple drug therapy," J. AIDS, vol. 12, pp. 111-115, 1998.
13. 3," presented at the 8th Conf. Retroviruses and Opportunistic Infections, Chicago, IL, Feb. 2001.
14. + lymphocyte dynamics in HIV infected individuals," Immunology, vol. 181, pp. 108-118, 1990.
15. M. Jeffrey, X. Xia, and I. K. Craig, "Controllability analysis of the chemotherapy of HIV/AIDS," in Proc. 15th IFAC Triennial World Congress Automatic Control, vol. Q; July 2002, pp. 127-132.
16. A. S. Joshi et al., "Population pharmacokinetics of efavirenzin phase II studies and relationship with efficacy," in Prog. and Abstr. 30th ICAAC, San Francisco, CA, Sept. 1999.
17. + lymphocyte count <200 cells/mL) is associated with increased risk of death," presented at the 8th Conf. Retroviruses and Opportunistic Infections, Chicago, IL, Feb. 2001.
18. D. Kirschner, "Using mathematics to understand HIV immune dynamics," AMS Notices, pp. 191-202, 1996.
19. D. Kirschner, S. Lenhart, and S. Serbin, "Optimal control of the chemotherapy of HIV," J. Math. Biol., vol. 35, pp. 775-792, 1997.
20. D. Kirschner and G. F. Webb, "A model for treatment strategy in the chemotherapy of AIDS," J. Math. Biol., vol. 58, pp. 367-390, 1996.
21. + lymphocytes," J. AIDS, vol. 24, pp. 352-362, 2000.
22. G. X. McLeod and S. M. Hammer, "Zidovudine: 5 years later," Ann. Int. Med., vol. 117, pp. 487-501, 1992.
23. M.A. Nowak and R. M. May, Virus Dynamics: Mathematical Principles of Immunology and Virology. New York: Oxford Univ. Press, 2000.
24. 3," presented at the 8th Conf. Retroviruses and Opportunistic Infections, Chicago, IL, Feb. 2001.
25. + T cells," Math. Biosci., vol. 114, pp. 81-125, 1993.
26. A. S. Perelson and P. W. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," SIAM Rev., vol. 41, pp. 3-44, 1999.
27. A.S. Perelson et al., "HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span and viral generation time," Science (Online Abstr.), vol. 271, pp. 1582-1586, 1996.
28. B. Ramratnam et al., "Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume apheresis," Lancet, vol. 354, pp. 1782-1785, 1999.
29. S. Skogestad and I. Postlethwaite, Multivariable Feedback Control: Analysis and Design, Chichestre, U.K.: Wiley, 1996.
30. + lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART," presented at the 8th Conf. Retroviruses and Opportunistic Infections, Chicago, IL, Feb. 2001.
31. + T cells by HIV and some Monte Carlo studies," Math. Biosci., vol. 147, pp. 173-205, 1998.
32. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, HIV/AIDS Treatment Information Service. USPHS. [Online]. Available: http://www.aidsinfo.nih.gov
33. L. M. Wein, S. A. Zenios, and M. A. Nowak, "Dynamic multidrug therapies for HIV: A control theoretic approach," J. Theor. Biol., vol. 185, pp. 15-29, 1997.
34. J. K. Wong, M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman, "Recovery of replication-competent HIV despite prolonged suppression of plasma viremia," Science, vol. 278, pp. 1291-1295, 1997.
35. X. Xia, "Estimation of HIV/AIDS parameters," in Proc. 15th IFAC Triennial World Congress, vol. Q, July 2002.